To include your compound in the COVID-19 Resource Center, submit it here.

Revolution revamp

How Revolution’s SHP-2 inhibitor persuaded Nextech to back $56 million series B

Revolution Medicines Inc.’s pivot to cancer and preclinical proof-of-concept data for its lead program convinced Nextech Invest to lead the company’s $56 million series B round.

Fellow new investors Casdin Capital and Schroder Adveq and existing investors Third Rock Ventures and The Column Group

Read the full 431 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE